BridgeBio reported positive top-line results from Propel 3, its global Phase 3 study of oral infigratinib in children with achondroplasia. The trial met its primary endpoint, showing statistically significant improvement in annualized height velocity versus placebo and recording the highest absolute AHV reported in a randomized achondroplasia study. Company guidance indicates plans to meet with regulators and pursue marketing applications later this year. The study enrolled ~110 pediatric patients and was overseen by BridgeBio’s clinical team; results were disclosed in company statements and corroborated by multiple industry outlets. Clinicians will watch safety signals such as transient hyperphosphatemia noted by BridgeBio, and competitors BioMarin and Ascendis face a new oral option in a market currently dominated by injectables.